News from calliditas therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 12, 2023, 23:15 ET Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy

Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global,...

Mar 12, 2023, 23:06 ET Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy

Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global,...

Feb 23, 2023, 01:41 ET Calliditas - Year-End Report, 2022

"2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for IgA nephropathy and a medication with the...

Feb 23, 2023, 01:34 ET Calliditas - Year-End Report, 2022

"2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for IgA nephropathy and a medication with the...

Feb 02, 2023, 03:46 ET Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Medicines and Healthcare products...

Feb 02, 2023, 03:44 ET Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Medicines and Healthcare products...

Jan 31, 2023, 02:22 ET Number of shares and votes in Calliditas Therapeutics

During January, Calliditas Therapeutics AB (publ) has issued 7,500 common shares connected to the company's long term incentive program 2019/2022....

Dec 30, 2022, 03:03 ET China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE)...

Dec 30, 2022, 03:00 ET China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE)...

Dec 30, 2022, 02:16 ET Number of shares and votes in Calliditas Therapeutics

During December, Calliditas Therapeutics AB (publ) has issued 415,000 common shares connected to the company's long term incentive program 2019/2022. ...

Dec 20, 2022, 22:08 ET Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022

Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO Renée Aguiar-Lucander has net...

Dec 20, 2022, 22:06 ET Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022

Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO Renée Aguiar-Lucander has net...

Dec 13, 2022, 03:04 ET Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan

Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") announced today that they have entered into an exclusive license...

Dec 13, 2022, 03:01 ET Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan

Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") announced today that they have entered into an exclusive license...

Dec 09, 2022, 02:10 ET Calliditas to host fireside chat with its China commercial partner, Everest Medicines

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a fireside chat with its commercial partner Everest Medicines...

Dec 09, 2022, 02:09 ET Calliditas to host fireside chat with its China commercial partner, Everest Medicines

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a fireside chat with its commercial partner Everest Medicines...

Nov 15, 2022, 02:45 ET Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Chinese regulatory authority National...

Nov 15, 2022, 02:39 ET Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Chinese regulatory authority National...

Nov 14, 2022, 01:13 ET Calliditas Therapeutics: Interim Report Q3, 2022

"On July 15th the European Commission issued the conditional marketing authorization for Kinpeygo, which marked the first time that any drug has...

Nov 14, 2022, 01:11 ET Calliditas Therapeutics: Interim Report Q3, 2022

"On July 15th the European Commission issued the conditional marketing authorization for Kinpeygo, which marked the first time that any drug has...

Nov 07, 2022, 03:15 ET Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a Key Opinion Leader (KOL) Fireside Chat on the IgA Nephropathy...

Nov 07, 2022, 03:13 ET Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a Key Opinion Leader (KOL) Fireside Chat on the IgA Nephropathy...

Oct 21, 2022, 04:27 ET Calliditas Therapeutics' nomination committee composition for the AGM 2023

The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting in 2017, consists of:...

Oct 19, 2022, 10:09 ET Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA Nephropathy

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced Kidney International has published the successful...

Oct 19, 2022, 10:03 ET Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA Nephropathy

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced Kidney International has published the successful...